- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03041012
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART (eCLEAR)
September 3, 2021 updated by: Aarhus University Hospital
Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial
To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted among ART naïve HIV-1-infected patients.
Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalborg, Denmark
- Department of Infectious Diseases
-
Aarhus, Denmark, 8200
- Dept. of Infectious Diseases, Aarhus University Hospital
-
Hvidovre, Denmark
- Department of Infectious Diseases
-
København, Denmark
- Department of Infectious Diseases
-
Odense, Denmark
- Department of Infectious Diseases
-
-
-
-
-
London, United Kingdom
- Imperial College Healthcare NHS Trust
-
London, United Kingdom
- Guy's and St Thomas'
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented HIV-1 infection
- CD4+ T cell count >200/µL on last visit prior to study entry
- ART naïve
- Able to give informed consent
Exclusion Criteria:
- Any significant acute medical illness (not including primary HIV infection) in the past 8 weeks
- Any evidence of an active AIDS-defining opportunistic infection
- Active alcohol or substance use that, in the Investigator's opinion, will prevent adequate compliance with study therapy
The following laboratory values at screening, but the values can be repeated within the screening period, but test results must be available before baseline (day 0) and checked for eligibility:
- Hepatic transaminases (AST or ALT) ≥3 x upper limit of normal (ULN)
- Serum total bilirubin ≥3 ULN
- Estimated glomerular filtration rate (eGFR) ≤60 mL/min (based on serum creatinine or other appropriate validated markers)
- Platelet count ≤100 x10^9/L
- Absolute neutrophil count ≤1x10^9/L
- Serum potassium, magnesium, phosphorus outside ≥1.5 ULN/LLN
- Total calcium (corrected for serum albumin) or ionized calcium ≥1.5 ULN/LLN
- Hepatitis B or C infection as indicated by the presence of hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood
- ECG at screening that shows QTc >450 ms when calculated using the Fridericia formula from either lead V3 or V4 [86]
Use of:
- Warfarin or warfarin-derivatives
- HDACi
- An agent definitely or possibly associated with effects on QT intervals within 2 weeks of screening
- Drugs that induce or inhibit CYP3A4 or P-gp
History of:
- Clinically significant cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for Torsades de pointes (e.g. heart failure)
- Malignancy or transplantation, including skin cancers or Kaposi sarcoma
- Diabetes mellitus
- Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days prior to study entry
- Known resistance to >2 classes of ART
- Known hypersensitivity to the components of romidepsin, 3BNC117 or their analogues
- Women who are pregnant or breastfeeding, or with a positive pregnancy test during screening or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method of non-estrogen containing contraceptions (according to the Danish Medicines Agency guidelines) to avoid pregnancy for the 3 week study period and 4 weeks after study treatment or until undetectable plasma HIV-1 RNA using standard assays
- Males or females who are unwilling or unable to use barrier contraception during sexual intercourse for the 3-week study period, and 4 weeks after study treatment or until undetectable plasma HIV-1 RNA using standard assays
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: antiretrovirals
Standard of care
|
Combination antiretroviral therapy
Other Names:
|
Active Comparator: antiretrovirals + romidepsin
Standard of care + LRA
|
Combination antiretroviral therapy
Other Names:
5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
Other Names:
|
Active Comparator: antiretrovirals + 3BNC117
Standard of care + bNAb
|
Combination antiretroviral therapy
Other Names:
30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
Other Names:
|
Active Comparator: antiretrovirals + romidepsin + 3BNC117
Standard of care + LRA + bNAb
|
Combination antiretroviral therapy
Other Names:
5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
Other Names:
30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma HIV RNA kinetics
Time Frame: 3 months
|
Time to undetectable (<20 c/mL)
|
3 months
|
Quantification of the size of the proviral HIV reservoir
Time Frame: 1 year
|
Copies of total HIV-1 DNA per 10⁶ CD4+ T cells as measured by digital droplet PCR
|
1 year
|
Time to viral rebound during ATI
Time Frame: 12 weeks
|
Days from stopping ART to plasma HIV RNA >5,000 on two consecutive measurements
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment emerging events (Safety and tolerability)
Time Frame: 1 year
|
Frequence and severity of adverse events (AE), adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and suspected unexpected serious adverse reactions (SUSAR).
|
1 year
|
Quantification of the intact proviral DNA
Time Frame: 1 year
|
Intact HIV-1 DNA in CD4+ T cells (copies per million cells) as measured by dd-PCR.
|
1 year
|
Quantification of HIV mRNA and/or p24 positive cells
Time Frame: 30 days from study entry
|
Frequency of mRNA/p24 postive per 1 million CD4+ T cells by FISH-flow
|
30 days from study entry
|
Immune reconstitution
Time Frame: 1 year
|
Absolute CD4+ and CD8+ T cell count
|
1 year
|
Analytic treatment interruption (ATI) study
Time Frame: 64 weeks
|
Time to first plasma HIV RNA >5000 c/mL
|
64 weeks
|
Impact of pre-ART virus sensitivity to 3BNC117 on ATI outcomes
Time Frame: Baseline and at viral rebound
|
3BNC117 sensitivity determined by PhenoSense and/or HIV env sequencing
|
Baseline and at viral rebound
|
T cell mediated HIV specific immunity
Time Frame: First of 365 days
|
T cell immunity as determined by the HIV AIM assay
|
First of 365 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma cytokine and immune activation biomarker levels
Time Frame: 1 year
|
Soluble IL-6, sCD14, sCD163
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2017
Primary Completion (Actual)
August 20, 2021
Study Completion (Anticipated)
December 30, 2021
Study Registration Dates
First Submitted
January 20, 2017
First Submitted That Met QC Criteria
January 31, 2017
First Posted (Estimate)
February 2, 2017
Study Record Updates
Last Update Posted (Actual)
September 13, 2021
Last Update Submitted That Met QC Criteria
September 3, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- eCLEAR-001
- 2015-002234-53 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol.
Data to be shared includes deidentified data points in published, peer-reviewed articles.
Additional, related documents will also be available (study protocol, informed consent form).
Data will become available following publication with no planned end date.
IPD Sharing Time Frame
Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol.
Data will become available following publication with no planned end date.
IPD Sharing Access Criteria
Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable).
Proposal should be addressed to olesoega@rm.dk.
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Antiretrovirals
-
Marie-Josée BrouilletteFonds de la Recherche en Santé du Québec; CIHR Canadian HIV Trials NetworkTerminatedHIV - Human Immunodeficiency Virus | Cognitive SymptomsCanada
-
University of California, Los AngelesTulane University; Los Angeles LGBT CenterActive, not recruitingHuman Immunodeficiency VirusUnited States
-
University of LouisvilleActive, not recruitingHIV-1-infectionUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); Gilead Sciences; UZ-UCSF Collaborative...Completed